Relay Therapeutics, one of FierceBiotech’s Fierce 15 companies named in September 2017, announced the successful completion of a $63 million Series B financing today, bringing total dollars raised to $120 million. Relay was founded to develop breakthrough medicines based on the study of protein motion and the relationship between that motion and the function of proteins.
Bringing together the latest scientific advances in structural biology, biophysics, computation, chemistry and biology, Relay’s drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function. By applying this approach and by focusing on disease-causing targets, Relay aims to develop breakthrough medicines for patients in need. The company’s initial programs are focused on developing therapeutics in oncology.
The Series B financing was led by BVF Partners, with participation from new investors GV (formerly known as Google Ventures), Casdin Capital, EcoR1 Capital and Section 32. Third Rock Ventures and Alexandria Venture Investments, who were part of the Series A round, also participated in this B round.
Relay Therapeutics’ platform, focused on understanding protein motion, represents a paradigm shift in drug discovery. The company’s pipeline has already delivered impressive early results and we’re excited to be a part of Relay’s future.
– Kanishka Pothula, Managing Director at BVF Partners and new member of Relay Therapeutics’ Board of Directors
We are pleased to have the confidence of these seasoned biotechnology investors in our integrated protein motion-based platform. Together with our dedicated team, we will continue to advance our pipeline towards delivering transformative targeted therapies to patients.
– Sanjiv Patel, MD, President and CEO of Relay Therapeutics.
Please email us at [email protected] to see our Case Studies and Testimonials.